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Limitations in the current therapeutic strategies for the prevention of progression of
chronic kidney disease (CKD) to end stage renal disease has been a drawback to
improving patient recovery. It is therefore imperative that a solution is found to alleviate
this problem and improve the health and well-being of patients overall. Aristolochic acid
(AA) induced nephropathy, a type of nephrotoxic CKD is characterised by cortical tubular
injury, inflammation, leading to interstitial fibrosis. Extracellular vesicles derived from
human bone marrow mesenchymal stem cells (MSC-EVs) display therapeutic properties
in various disease models including kidney injury. In the current study, we intended
to investigate the ability of MSC-EVs on ameliorating tubular injury and interstitial
fibrosis in a mouse model of aristolochic acid nephropathy (AAN). The chronic model
of AAN is comprised of an intraperitoneal injection of AA in NSG mice, followed by
a three-day incubation period and then inoculation of MSC-EVs intravenously. This
routine was performed on a weekly basis for four consecutive weeks, accompanied by
the monitoring of body weight of all mice. Blood and tissue samples were collected
post sacrifice. All animals administered with AA developed kidney injury and renal
fibrosis. A gradual loss of body weight was observed, together with a deterioration in
kidney function. Although no significant recovery was observed in weight loss following
treatment with MSC-EVs, a significant reduction in: blood creatinine and blood urea
nitrogen (BUN), tubular necrosis, and interstitial fibrosis was observed. In addition,
infiltration of CD45 positive immune cells, fibroblasts, and pericytes which were elevated
in the interstitium post AA induced injury, were also significantly reduced by MSC-EVs.
Kidneys were also subjected to molecular analyses to evaluate the regulation of pro-
fibrotic genes. MSC-EVs significantly reduced AA induction of the pro-fibrotic genes
α-Sma, Tgfb1 and Col1a1. A downregulation in pro-fibrotic genes was also observed
in fibroblasts activated by AA injured mTECs in vitro. Furthermore, meta-analyses of
miRNAs downregulated by MSC-EVs, such as miR21, revealed the regulation of multiple
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pathways involved in kidney injury including fibrosis, inflammation, and apoptosis. These
results therefore suggest that MSC-EVs could play a regenerative and anti-fibrotic role
in AAN through the transfer of biologically active cargo that regulates the disease both
at a protein and genetic level.
Keywords: aristolochic acid nephropathy, extracellular vesicles, mesenchymal stem cells, chronic kidney
disease, miRNA, fibrosis
INTRODUCTION
The current limitation in effective therapeutic strategies, available
to prevent the progression of chronic kidney disease (CKD)
toward end stage renal disease, has been a major drawback in
improving patient recovery. It is therefore imperative that a
solution is found to alleviate this problem and improve the overall
health and well-being of patients (Shea and Booth, 2019).
Aristolochic acids (AA) are a group of toxins that are enriched
in plants of the genus Aristolochia and Asarum, commonly found
worldwide (Han et al., 2019). These plants have been regularly
used as part of traditional herbal therapy for the treatment of
various ailments as well as slimming (Jadot et al., 2017). In
the early 1990s, various women who were on a similar weight
loss regimen, consisting of Chinese herbs, presented with a
rapidly progressive form of CKD, known as Chinese herbal
nephropathy (CHN) (Jadot et al., 2017). In addition, another
form of nephropathy, more prominent in the Balkan region of
Eastern Europe, hence known as Balkan endemic nephropathy
(BEN), also exhibited similarities to CHN (Jelakovic et al., 2019).
Further investigations led to the discovery of AA in the Chinese
herbs, as the cause of CHN. Meanwhile, the contamination of
the weed species Aristolochia clematitis (rich in AA) in wheat
consumed in the Balkan regions was identified to be the cause of
BEN (Jadot et al., 2017). As a result, both CHN and BEN are now
collectively classified as aristolochic acid nephropathy (AAN)
(Jadot et al., 2017). AAN is mainly characterised by tubular
damage and atrophy accompanied with interstitial nephritis
and extensive fibrosis. In addition, 40% of cases manifest with
urothelial carcinoma due to the DNA adducting properties of
AA. Although extensive research has been done over the years
to elucidate the underlying mechanisms of AAN, no effective
therapeutic regimen is available as of yet (Han et al., 2019).
Current advances in the field of regenerative medicine
have generated an interest in the development of alternative
treatments that would aim not only to alleviate the symptoms,
but also to repair and regenerate injured tissues. In particular,
therapies based on adult stem cells have become a promising
strategy due to their abilities of self-renewal, multipotency,
Abbreviations: α-Sma, alpha smooth muscle actin; AA, aristolochic acid; AAN,
aristolochic acid nephropathy; AKI, acute kidney injury; BEN, Balkan endemic
nephropathy; BUN, Blood urea nitrogen; CHN, Chinese herbal nephropathy;
CKD, chronic kidney disease; DMEM, Dulbecco’s minimum essential medium;
DMSO, dimethyl sulfoxide; EVs, extracellular vesicles; HLSC, human liver stem
cell; LTBP1, latent TGFb binding protein 1; MFI, mean fluorescence intensity;
mkCF, mouse kidney cortical fibroblast; MSC, mesenchymal stem cells; mTEC,
mouse tubular epithelial cell; PDGF, platelet derived growth factor; TGFb,
transforming growth factor beta; UUO, Unilateral ureter injury; WNT, Wingless-
related integration site.
and plasticity. Bone marrow derived mesenchymal stromal
cells (MSCs) are one of the most extensively studied stem
cell types, as they are easy to isolate/expand, and have a low
risk of forming teratomas. In addition, they have shown great
therapeutic potential in various experimental models of acute and
chronic kidney disease. For instance, Morigi et al. (2004) reported
that murine bone marrow derived MSCs in a mouse model of
cisplatin-induced acute kidney injury (AKI) alleviated tubular
damage and improved renal function. Furthermore, Herrera et al.
(2004), in their mouse model of glycerol-induced AKI, also
showed a similar tubular regenerative effect attributed to the
engraftment of MSCs in the damaged kidney. Apart from AKI,
MSCs have also been reported to be therapeutically effective in
experimental CKD. For instance, bone marrow derived MSCs
attenuated tubulointerstitial injury, in a model of unilateral ureter
obstruction in mice (Xing et al., 2019) and promoted renal
repair, by limiting the dysfunction of podocytes and glomerular
progenitor cells, in a model of adriamycin-induced nephropathy
(Zoja et al., 2012). However, due to limitations in the expansion
of MSCs in vitro, the induction of senescence at an early passage,
and immunogenicity, has made the translation of experimental
findings to a more clinical setting rather challenging (Rota et al.,
2019). Various mechanisms have been suggested through which
MSCs exhibit their reno-protective effect. One such mechanism
is the packaging and release of biologically active factors in the
form of extracellular vesicles (EVs).
Extracellular vesicles are heterogeneous membrane bound
particles, naturally released by all cells in the body (Grange
et al., 2019a). They are classified according to their biogenesis,
whereby, EVs derived from multivesicular bodies are known
as exosomes and those released from the cell surface through
membrane blebbing are known as ectosomes (van der Pol et al.,
2012). EVs influence recipient cells, both locally and systemically,
through the transfer of their biologically active cargo (nucleic
acids, proteins, and lipids) (Bruno et al., 2019). In addition,
they can also induce epigenetic changes in injured target cells,
activating regenerative programmes (Derkus et al., 2017).
The regenerative capability of MSC-EVs has been very well
described in multiple models of kidney disease. For instance,
Bruno et al. (2009) demonstrated that MSC-EVs augmented the
recovery of injured tubular cells, by preventing apoptosis and
promoting proliferation, in a glycerol induced murine model
of AKI. In addition, the effect observed was similar to the
effects observed when injecting MSCs in the same model (Bruno
et al., 2009). In addition, Alzahrani (2019) showed through a
rat model of renal ischemia reperfusion injury, that exosomes
derived from MSC alleviate the disease. However, exosomes
isolated from melatonin preconditioned MSCs were even more
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effective in comparison to naïve MSC exosomes. This therefore
indicates the potential prospect of enhancing the therapeutic
effect of MSC-EVs through preconditioning. MSC-EVs have also
proven to be functional in toxic models of AKI, whereby renal
function together with the classic pathophysiological features
were significantly improved (Bruno et al., 2012; Reis et al., 2012).
Apart from AKI, MSC-EVs have also been shown to be effective
in various models of CKD. For instance, in a murine model
of diabetic nephropathy, Grange et al. (2019b) confirmed the
reversion of renal fibrosis and an improvement in renal function
post treatment with MSC-EVs. In other models of CKD, such as
the 5/6 nephrectomy model and the unilateral ureter obstruction
(UUO) model, MSC-EVs have proven to be effective in reducing
glomerulosclerosis and fibrosis (He et al., 2012, 2015). Recently,
we reported that also human liver stem cell-derived EVs (HLSC-
EVs) exhibit regenerative properties and are effective in reducing
fibrosis and improving overall kidney function in the current
model of AAN (Kholia et al., 2018).
The aim of the current study was therefore to evaluate whether
MSC-EVs exhibit any therapeutic effect similar to HLSC-EVs in
the CKD model of AAN.
MATERIALS AND METHODS
Cell Culture
Mesenchymal Stem Cells (MSC)
Human bone marrow MSCs purchased from Lonza (Basel,
Switzerland) were cultured in mesenchymal stem cell basal
medium (MSCBM, Lonza). Cells were sub-cultured after 15 days
following thawing from passage one and then after every
seven days for successive passages. EVs were isolated from cells
until passage six.
Murine Tubular Epithelial Cells (mTEC)
mTECs, isolated from kidneys of healthy female C57 mice [as
described previously by our lab (Bruno et al., 2009)], were
cultured in Dulbecco’s modified essential medium (DMEM)
supplemented with L-glutamine (5 mM), penicillin (50 IU/ml),
streptomycin (50 µg/ml) and 10% FCS (Euroclone, Milan, Italy).
Mouse Kidney Cortical Fibroblasts (mkCF)
mkCFs, were isolated from the kidneys of healthy male CD1
mice [as previously described by our lab (Kholia et al., 2018)],
were cultured in DMEM high glucose (Euroclone, Milan, Italy)
supplemented with L-glutamine (5 mM), penicillin (50 IU/ml),
streptomycin (50µg/ml), 10 ml HEPES (Sigma Aldrich), and 10%
FCS (Euroclone, Milan, Italy).
Isolation and Characterisation of EVs
EVs were isolated from supernatants, obtained from MSCs
(1 × 106 cells/T150 flask) following overnight (18 h) starvation
in serum free Roswell Park Memorial Institute Medium (RPMI)
(Euroclone, Milan, Italy). The viability of cells post starvation
was 98%, as confirmed by Trypan blue exclusion staining. Briefly,
supernatants were subjected to centrifugation at 3000 g for
15 min at 4◦C, followed by microfiltration using a 0.22 µm
vacuum filter unit (Millipore, United States), for the removal of
cell debris and apoptotic bodies. The effective removal of cell
debris by this procedure was checked by electron microscopy.
In order to pellet EVs, the purified supernatant was further
ultracentrifuged at 100,000 g for 2 h at 4◦C using the SW70Ti
rotor in a Beckman Coulter Optima L-90 K ultracentrifuge
(Beckman Coulter, Fullerton, CA, United States). The resulting
pellet was resuspended in RPMI supplemented with 1% dimethyl
sulfoxide (DMSO) and stored at -80◦C.
Characterisation of EVs was performed according to the
criteria suggested by the ISEV position paper (Thery et al.,
2018). The expression of surface markers was evaluated using
the human cytofluorimetric bead-based MACSPlex exosome
kit (Miltenyi Biotec, Germany) according to manufacturer’s
protocol. Briefly, three independent MSC-EV preparations
consisting of approximately 1 × 109 MSC-EVs/preparation were
diluted in MACSPlex buffer (MPB) to a final volume of 120µl in a
1.5 ml microcentrifuge tube. This was followed by the addition of
15 µl of MACSPlex exosome capture beads (containing a cocktail
of 39 different exosomal marker epitopes). The EVs on capture
beads were counterstained by adding 5 µl of APC-conjugated:
anti-CD9, anti-CD63, and anti-CD81 detection antibodies to
each of the tubes and incubating for 1 h at room temperature in
the dark on an orbital shaker at 450 rpm. Post incubation, the
beads were subjected to first washing with 1 ml of MPB at 3,000 g
for 5 min, followed by a longer washing step by incubating the
beads in 1 ml of MPB on an orbital shaker (as before) for 15 min.
After this step, the beads were centrifuged at 3,000 g for 5 min and
the supernatant was carefully aspirated leaving a residual volume
of 150 µl per tube for acquisition. Flow cytometric analysis
was performed using the Cytoflex flow cytometer (Beckman
Coulter, Brea, CA, United States) whereby approximately 5000–
8000 single bead events were recorded per sample. The median
fluorescence intensity (MFI) for all 39 exosomal markers were
corrected for background and gated based on their respective
fluorescence intensity as per manufacturer’s instructions.
Transmission electron microscopy was performed as
described previously (Kholia et al., 2018) using negative staining
with NanoVan (Nanoprobes, Yaphank). Samples were examined
by a Jeol JEM 1010 electron microscope (Joel, United States).
Electron microscopy revealed the presence of vesicles ranging
from 35 to 100 nm. Western blot analysis of EV protein was
performed to confirm the presence of the classical exosomal
marker CD63, and the absence of the cytoplasmic marker GM130
(positive in MSC cell lysates). Particle size and concentration of
purified EVs was assessed with the Nanosight NS300 (NanoSight,
Amesbury, United Kingdom) equipped with a 405 nm laser
using the NTA 1.4 Analytical Software as described previously
(Herrera Sanchez et al., 2014).
In vitro Model of Aristolochic Acid
Nephropathy
In order to elucidate the effects of MSC-EVs on cortical renal
fibroblasts, an in vitro model of AA-induced fibrosis was set.
Briefly, 1.5 × 104 mTECs were treated with 100 µM AA for
4 h in 24 well cell culture inserts (1.0 µm pore) (Thermo Fisher
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Scientific). mTECs without AA treatment served as controls.
Post incubation, the mTECs were washed once with PBS and
co-cultured with mkCF cells (already seeded the day before
in a 24 well plate at a concentration of 2 × 104 cells/well)
for five days at 37◦C in the presence or absence of MSC-EVs
at a concentration of 75,000 EVs/cell (MSC-EVs were added
to the lower compartment with fibroblasts). Post incubation,
mkCFs were analysed for fibrotic gene expression by qRT-PCR.
Fibroblasts co-cultured with healthy mTECs served as controls.
Mouse Model of Aristolochic Acid
Induced Nephropathy
Animal studies were conducted according to the guidelines for
the Care and Use of Laboratory Animals set by the National
Institute of Health. All procedures were approved by the
Ethics Committee of the University of Turin and the Italian
Health Ministry (authorisation number: 766/2016-PR). AAN was
instigated in male NOD/SCID/IL2Rγ KO (NSG) mice (bred
at the animal facility in the Molecular Biotechnology Centre)
(6/8 weeks old; n = 12) by intraperitoneal injections of 4 mg/kg
of AA diluted in 250 µl of PBS final volume (Santa Cruz
Biotechnology, Santa Cruz, CA, United States) (AA was dissolved
in DMSO at a concentration of 10 mg/ml) once a week for
four consecutive weeks (Figure 2A). A group of mice were
injected with MSC-EVs (n = 9) intravenously at a concentration
of 1 × 1010 EVs/ml/mouse or vehicle alone (PBS) (n = 5; as
control) three days after AA administration on a weekly basis
(Figure 2A). Mice were sacrificed after four weeks and subjected
to multi-parameter analyses as mentioned below. The use of
immunodeficient mice was preferred in this study to avoid an
immunogenic reaction due to repeated injections of MSC-EVs.
During AA administration, healthy mice were injected with the
volume of DMSO (equivalent to 4 mg/kg of AA) diluted in 250 µl
of PBS final volume.
Total Body Weight and Kidney Function
Body weight of mice was recorded to assess their general health
on a weekly basis prior to AA injections and at the end
of the experiment just before sacrificing. Kidney function of
mice from all experimental groups was evaluated by measuring
blood plasma creatinine after sacrificing using a colorimetric
microplate assay based on the Jaffe reaction (Quantichrom
Creatinine Assay, BioAssay systems, Hayward, CA, United States)
as per manufacturer’s protocol. Blood urea nitrogen (BUN)
was measured by direct quantification of plasma urea with a
colorimetric assay kit according to the manufacturer’s protocol
(Quantichrom Urea Assay, BioAssay Systems, Hayward, CA,
United States).
RNA Extraction and qRT-PCR
Total RNA was extracted from mouse tissue as described
previously (Kholia et al., 2018). Briefly, mouse renal tissue
was resuspended in 1 ml of TRIzolTM solution (Ambion,
Thermofisher) in microcentrifuge tubes and homogenised in a
Bullet blender (Next Advance Inc, NY, United States) at a speed
of 8 rpm for 3 min using 3.2 mm size zirconium beads. The
tubes were then placed on a tube rotator at 4◦C for 30 min,
followed by centrifugation at 12,000 g for 15 min at 4◦C.
Supernatant was transferred to clean tubes and subjected to RNA
isolation using the miRNeasy mini kit (Qiagen, Frederick, MD,
United States), according to the manufacturer’s protocol. For
the isolation of RNA from cells, 700 µl of TRIzolTM solution
was added to cells in the wells and incubated for 10 min on
a shaker. The mixture was then transferred to 1.5 ml RNAse
free tubes and subjected to RNA isolation using the miRNeasy
mini kit (Qiagen, Frederick, MD, United States), according to
the manufacturer’s protocol. Total RNA was quantified using the
NanoDrop2000 spectrophotometer (Thermo Fisher, Waltham,
MA, United States) and either used immediately or stored at
-80◦C until further use.
cDNA was synthesised by retro-transcribing 200 ng of total
RNA using the High Capacity cDNA reverse transcription kit
(Thermo Fisher, Waltham, MA, United States), according to
the manufacturer’s protocol. qRT PCR was performed using
the StepOnePlus RT-PCR machine (Thermo Fisher, Waltham,
MA, United States) in 20 µl reactions with Power SYBR Green
PCR Master Mix (Thermo Fisher, Waltham, MA, United States)
and specific oligonucleotide primers (Table 1) (MWG−Biotech,
Eurofins Scientific, Brussels, Belgium). Data were analysed using
11Ct method with Gapdh as endogenous control.
Validation of the expression of specific miRNAs obtained
from the Fireplex R© assay by ABCAM, was performed as follows.
Total RNA was isolated from ten (8 µm) formalin fixed
parafilm embedded (FFPE) sections (n = 3/condition) using
the RecoverALLTM Total Nucleic acid isolation kit for FFPE
(Thermo Fisher, Waltham, MA, United States) according to
the manufacturer’s protocol. The total RNA from each mouse
(200 ng of input RNA) was reverse transcribed, using the
miScript Reverse Transcription Kit (Thermo Fisher, Waltham,
MA, United States) and the cDNA was subjected to RT-PCR, to
validate the miRNAs of interest. Experiments were performed in
triplicate using 3 ng of cDNA for each reaction as described by the
manufacturer’s protocol (Qiagen). The following miRNAs were
TABLE 1 | List of Primers used for qRT-PCR.
Gene Primer Sequence 5′-3′
m_Col1a1 Forward ATC TCC TGG TGC TGA TGG AC
m_Col1a1 Reverse ACC TTG TTT GCC AGG TTC AC
m_Tgfb1 Forward CGA AAG CCC TGT ATT CCG TCT
m_Tgfb1 Reverse GCA ACA ATT CCTGGC GTT ACC
m_α-Sma Forward CTG ACA GAG GCA CCA CTG AA
m_α-Sma Reverse CAT CTC CAG AGT CCA GCA CA
m_Ltbp1 Forward GGA GCC CGA AGT GGT AAC AG
m_Ltbp1 Reverse GAA TAG TTG AAA CCC CTG GGG
m_Gapdh Forward TGT CAA GCT CAT TTC CTG GTA TGA
m_Gapdh Reverse TCT TAC TCC TTG GAG GCC ATG T
hsa-miR-132-5p TAA CAG TCT ACA GCC ATG GTC G
hsa-miR-342-3p TCT CAC ACA GAA ATC GCA
hsa-miR-214-3p ACA GCA GGC ACA GAC AGG
hsa-RNU6b CGC AAG GAT GAC ACG CAA
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screened in all mice conditions: miR-132-5p, miR-342-3p, and
miR-214-3p with RNU6b as endogenous control.
Histological Analysis
Paraffin embedded renal tissues were cut in 5 µm-thick
sections and stained with haematoxylin and eosin (for tubular
damage and hyaline cast formation), or Masson’s Trichrome
(for interstitial fibrosis) (Bio-Optica, Milan, Italy), according to
the manufacturer’s protocols. Assessment of tubular necrosis
was performed by analysing 10 non-overlapping cortical
fields/section at a magnification of 400x (high power field, HPF)
using ImageJ software. Quantification of interstitial fibrosis was
performed by measuring collagenous fibrotic areas stained in blue
(sections stained with Masson’s trichrome) in 10 random cortical
fields/section from images taken at a magnification of 200x, using
multiphase image analysis with ImageJ software version 1.49s
(Schneider et al., 2012).
Immunohistochemical staining was performed as described
previously (Herrera Sanchez et al., 2014). Briefly, 5 µm sections
were deparaffinised, hydrated, and subjected to antigen-retrieval.
Endogenous peroxidase was removed using 5% H2O2. Sections
were blocked with 3% BSA/PBS and then incubated with
antibodies of interest: proliferating cell nuclear antigen (PCNA)
(1:400, Santa Cruz Biotechnology), α-smooth muscle actin
(α-SMA) (1:100, Ab7817, Abcam), S100A4 [Fibroblast specific
protein 1 (FSP-1)] (1:500, Ab41532, Abcam), and CD45 (1:500,
Ab10558, Abcam) overnight at 4◦C. The following day, after two
washes with PBS-tween 0.01%, the sections were incubated with
secondary horse radish peroxidase antibody (Pierce, Rockford,
IL, United States) for 1 h at room temperature. Sections were then
developed with diaminobenzidine (DAB) (Dako, Carpinteria,
CA, United States), counterstained with haematoxylin, and
analysed via microscopy.
For sections that required immunofluorescence double
staining, the slides were blocked with 3% BSA/PBS for 30 min
following antigen retrieval, permeabilised in 0.2% Triton-
X100/PBS for 6 min at 4◦C and then incubated with the
primary antibodies of interest: α-SMA (1:100, Ab7817, Abcam),
and platelet derived growth factor receptor beta (PDGFRβ,
1:50, Ab32570, Abcam) overnight at 4◦C. Secondary antibodies
were incubated with sections for 1 h at room temperature.
Following washes, the sections were stained with DAPI and
mounted with Fluorescent mounting media and analysed via
microscopy. Sections labelled only with secondary antibody
served as controls.
In order to evaluate changes in cell death, kidney
tissue sections were stained for DNA fragmentation using
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) according to the manufacturer’s protocol (Roche,
United Kingdom). Cell death was quantified by averaging the
numerical count of TUNEL-positive nuclei in 8 random cortical
fields/section from images taken at a high magnification of 400x,
using ImageJ software as mentioned above.
Fireplex miRNA Assay
The FirePlex multiplex miRNA allows a high-throughput analysis
of up to 65 literature validated peer-reviewed miRNA targets,
involved in kidney injury, by flow cytometry and efficient
analysis with the FirePlex Analysis Workbench Software. In order
to evaluate the regulation of miRNAs specifically involved in
kidney injury, formalin fixed paraffin embedded tissue slices
(in duplicate) from mice treated with AA (n = 3), AA mice
treated with MSC-EVs (n = 5), and healthy mice (n = 3) were
provided to Abcam to perform the assay specific to kidney
injury (kidney toxicity panel, ab219508, Abcam) as a service.
The samples were processed as per the published protocol.
Briefly, FFPE samples were mixed with 36 µl Digest Buffer,
20 µl water and 4 µl Protease Mix and incubated at 60◦C for
45 min with shaking. For each sample run, FirePlex Particles
(35 µl) were added to a well of a 96-well filter plate and filtered.
Twenty-five µl Hybe Buffer was added to each well followed by
1 ng of total RNA. The plate was incubated at 37◦C for 1 h
with shaking. After two washes with 1 × Rinse A, 75 µl of
1× Labeling Buffer was added per well. The plate was further
incubated at room temperature for 1 h with shaking. After
two washes with 1 × Rinse B and one wash with 1 × Rinse
A, a catch plate was added to the vacuum manifold and the
filter plate put under constant vacuum. Sixty five µl of 95◦C
RNAse-free water was added twice to each well to elute the
ligated sample. Thirty µl of this meltoff was added to a clean
PCR plate and mixed with 20 µl PCR master mix. The mixture
underwent 32 cycles of PCR amplification. Sixty µl of Hybe
Buffer was then added back to each well of the original particles
followed by 20 µl of the PCR product, and the plate was
incubated at 37◦C for 30 min with shaking. After two washes
with 1 × Rinse B and one with 1 × Rinse A, 75 µl of
1 × Reporting Buffer was added per well and the plate was
incubated at room temperature for 15 min on a shaker. Post
incubation, the plate was washed twice with 1 × Rinse A, and
then 175 µl of Run Buffer was added to each well. The samples
were then scanned on an EMD Millipore Guava 6HT flow
cytometer (MilliporeSigma, Germany) and the Flow cytometry
quantification data was analysed with the FirePlex Analysis
Workbench software (Abcam, Cambridge, MA, United States)
whereby, the Fluorescence intensity values across all samples
were normalised using the geNorm algorithm.
Bioinformatic Analyses
Data from the Fireplex miRNA assay were further analysed using
FirePlex R© Analysis Workbench Software version 2.0 (Abcam)
Fireplex Analysis Workbench software (Abcam). Gene target
prediction was performed with miRWalk 3.0 considering only
miRNAs targeting the 3′UTR sequence and a score above
0.95 (Dweep et al., 2014). Panther Classification System online
software was used for pathway enrichment analysis (Thomas
et al., 2003). Only pathways with a minimum number of five
genes were considered in the classification.
Statistical Analyses
All data obtained were analysed using GraphPad Prism 6.0.
Results are expressed as mean ± standard deviation (SD) or
standard error of the mean (SEM) where indicated. Statistical
analyses were performed by employing the one way analyses of
variance (ANOVA) or two-way ANOVA with a multi comparison
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FIGURE 1 | Characterisation of MSC-EVs. (A) Multiplex bead-based flow cytometry assay was used to characterise MSC-EV surface antigens. Thirty nine
multiplexed populations of dye-labeled antibody-coated capture beads containing established exosomal markers were incubated with MSC-EVs and analysed by
flow cytometry. Experiments were performed with three different samples. (B) Nanoparticle tracking analyses showing the size distribution and quantity of MSC-EVs
purified by differential ultracentrifugation. (C) Representative transmission electron microscopy showing MSC-EVs (original magnification 150,000X).
(D) Representative Western blot analysis of the exosomal marker CD63 (30–60 kDa) in MSC-EVs and negatively stained for GM130 (130 kDa) (MSC lysate was used
as positive control).
test where appropriate. A p-value of <0.05 was considered
statistically significant.
RESULTS
Characterisation of MSC-EVs
EVs were evaluated for typical expression markers using the
MACS multiplex bead-based flow cytometry assay described
recently (Koliha et al., 2016; Wiklander et al., 2018). The assay
involves incubating EVs with a cocktail of 39 different bead
populations, each representing a typical exosomal surface antigen
(37 markers and 2 isotypic controls). EVs bound to beads are
counterstained with a cocktail of APC conjugated detection
antibodies of commonly used exosome markers anti-CD9, anti-
CD63, and anti-CD81 and analysed by flow cytometry. Data
analysis revealed that EVs were positive for the typical MSC
markers such as CD29, CD44, CD49e, CD105, CD146, as well
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FIGURE 2 | Induction of nephropathy in NSG mice by aristolochic acid intoxication. (A) Schematic representation of the experimental design for aristolochic acid
nephropathy (AAN) in vivo showing the days of administration of AA or Human bone marrow mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) for
4 weeks (wk). (B) Mice body weight was measured weekly before AA injections for 4 weeks. The body weight is represented as percentage weight change.
A two-way analyses of variance (ANOVA) was performed with Bonferroni’s multi comparison test; Data are expressed as mean ± SEM of seven mice per group. **p
and ***p < 0.001 AA vs. control. (C) Plasma creatinine and (D) BUN levels in mice treated with vehicle alone or mice injected with AA or AA mice injected with
MSC-EVs (n = 7 mice per group). **p < 0.001 AA vs. control and AA + MSC-EVs vs. AA. Data are expressed as mean ± SEM; a one way ANOVA with Bonferroni’s
multi comparison test was performed.
as for the exosomal positive tetraspanins CD9, CD63, and CD81
(Figure 1A). In addition, EVs were negative for the endothelial
marker CD31 and epithelial marker CD326, therefore confirming
their mesenchymal origin (Figure 1A). Furthermore, Nanosight
analysis revealed the size of EVs to be in the typical range of 30-
300 nm, which was further confirmed by transmission electron
microscopy (Figures 1B,C). Western blot analysis showed that
EVs were positive for CD63 and negative for the cell cytoplasmic
marker GM130 (Figure 1D).
MSC-EVs Ameliorate AA Induced Kidney
Damage
Weight loss is considered to be one of the main macro symptoms
of AAN. Therefore, we monitored the total body weight of each
mouse on a weekly basis prior to AA administration (Figure 2A).
Mice injected with AA lost weight significantly from week two
onward compared to healthy mice (Figure 2B). Treatment with
MSC-EVs, post AA administration, did not ameliorate the loss of
weight induced by AA throughout the course of the pathology
(Figure 2B). As a parameter of kidney function, the plasma
creatinine and BUN levels were also evaluated in all mice groups
at sacrifice. Data analysis revealed a significant increase in plasma
creatinine and BUN levels of mice injected with AA compared
to healthy controls (Figures 2C,D). In contrast, AA mice treated
with MSC-EVs had significantly reduced levels of both plasma
creatinine and BUN in comparison with mice injected with AA
alone (Figures 2C,D).
Immunohistochemical analyses were performed to evaluate
the morphological changes of kidney tissue from all the
experimental groups. Kidney tissue of mice that had been injected
with AA alone had severe damage of the proximal tubules,
formation of hyaline casts, and development of interstitial
fibrosis, compared to healthy controls (Figures 3A,B). On
the other hand, mice that received treatment with MSC-
EVs showed a significant amelioration in kidney damage,
whereby there was a marked reduction in tubular necrosis
(H&E staining) and interstitial fibrosis, as observed by Masson’s
trichrome staining (Figures 3A,B). This was further confirmed
by the histological score (obtained by quantifying tubular
necrosis and interstitial fibrosis in kidney sections from all
experimental groups) whereby, mice inoculated with MSC-
EVs significantly reduced the number of necrotic tubules, and
interstitial fibrosis compared to AA injured mice (Figures 3C,D).
Furthermore, assessment of proliferation and apoptosis through
PCNA/TUNEL staining showed a significant increase in PCNA
positive cells (Figure 4A) and a decrease in TUNEL positive
apoptotic cells (Figure 4B) in AA mice treated with MSC-EVs
compared to mice injected with AA alone.
Activation of fibrogenic cells, as assessed by α-SMA staining,
was found to be significantly elevated in mice injected with AA
compared to healthy controls (Figure 5A). Interestingly, this
elevation was significantly reduced in AA mice treated with
MSC-EVs as evaluated by morphometric analyses (Figure 5A).
Infiltration of FSP-1 positive cells, and CD45 positive
inflammatory cells was also assessed through staining with their
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FIGURE 3 | Histological analyses of AAN in vivo model. (A) Micrographs representing H&E stained renal tissue from healthy mice injected with the vehicle alone
(control), or mice injected with AA, or AA mice treated with MSC−EVs. Original magnification at 400X. (B) Micrographs representing Masson’s trichrome stained
renal sections from control, AA or MSC-EV treated AA mice. The blue stain is collagen fibres signifying interstitial fibrosis. Original magnification at 200X.
(C) Histological score of tubular necrosis in AAN mice experimental groups. Mice treated with AA had significantly high levels of tubular necrosis, which was reduced,
on treatment with MSC-EVs. Data represent mean ± SEM of tubular necrosis observed under high power field (original magnification: 400X). A one way ANOVA with
Bonferroni’s multi comparison test was performed. ***p < 0.001 AA vs. control or AA+MSC−EVs vs. AA. (D) Histological quantification of interstitial fibrosis in AAN
mice experimental groups by multiphase image analysis of 10 fields per section. Data represent mean ± SEM; A one way ANOVA with Bonferroni’s multi comparison
test was performed. ***p < 0.001 AA vs. control, **p < 0.01 MSC−EV vs. AA.
respective antibodies. Mice treated with AA had a significantly
higher presence of both FSP-1 and CD45 cells compared to
healthy controls (Figures 5B,C). In contrast, treatment of
AA mice with MSC-EVs significantly reduced the infiltration
of FSP-1 and CD45 positive cells (Figures 5B,C). This was
further confirmed by histological score analyses which revealed
a significant difference between the three experimental groups,
exhibiting an ameliorating effect of MSC-EVs (Figures 5B,C).
Pericytes are perivascular cells that migrate to the interstitium
and differentiate into myofibroblasts during renal interstitial
fibrosis. The presence of pericytes/myofibroblasts was therefore
assessed through PDGFrβ/α-SMA co-staining. Data analyses
revealed a significant rise in PDGFrβ/α-SMA positive cells in
the kidney interstitium following AA induced injury compared
to healthy controls (Figure 5D). However, AA mice treated
with MSC-EVs had significantly lower levels of PDGFrβ/α-SMA
positive cells compared to AA mice (Figure 5D).
MSC-EVs Revert AA Induced
Upregulation of Pro-fibrotic Genes in
AAN Mice Kidneys
Real time PCR of kidney tissue from the experimental mice
groups revealed that mice treated with AA alone had significantly
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FIGURE 4 | Representative micrographs of PCNA and TUNEL stained renal tissue. (A) Proliferating cell nuclear antigen (PCNA) staining of control, AA, or AA mice
treated with MSC-EVs. Histological score of PCNA positive cells in AAN mice experimental groups observed under high power with an original magnification of 400X.
An increase in PCNA positive cells was observed in MSC-EV treated mice renal tissue. Data represent mean ± SEM. A one way ANOVA with Bonferroni’s multi
comparison test was performed. *p < 0.01 AA vs. control, or ***p < 0.05 AA+MSC−EVs vs. AA (B) TUNEL staining of control, AA, or AA mice treated with
MSC-EVs. Histological score of% of apoptotic cells (by TUNEL staining) in AAN mice experimental groups observed under high power with an original magnification
of 400X. A decrease in TUNEL positive cells was observed in MSC-EV treated mice renal tissue. Data represent mean ± SEM. A one way ANOVA with Bonferroni’s
multi comparison test was performed. **p < 0.01 AA vs. control, or **p < 0.05 AA+MSC−EVs vs. AA. Original magnification at 400X.
elevated levels of the pro-fibrotic genes: alpha Smooth muscle
actin (α-Sma), Collagen 1a1 (Col1a1) and Transforming Growth
Factor beta 1 (Tgfb1) (Figures 6A–C) compared to healthy
controls. However, AA mice, that had received MSC-EVs,
exhibited significantly lower levels of all three pro-fibrotic
genes (Figures 6A–C) in comparison with AA injured mice.
Furthermore, we also evaluated the regulation of the gene
Latent-Transforming Growth Factor beta-binding protein 1
(Ltbp1), that codes for the LTBP1 protein, involved in the
activation of TGFβ1. Mice treated with AA had significantly
upregulated levels of the Ltbp1 gene which was found to be
significantly downregulated in AA mice treated with MSC-
EVs (Figure 6D).
MSC-EV Treatment Induced the
Downregulation of Pro-fibrotic Genes in
Fibroblasts in vitro
In order to elucidate the role of MSC-EVs on activated renal
fibroblasts, an in vitro model in which AA injured mTECs
were co-cultured with kidney fibroblasts in a transwell system
was set-up (Figure 7A). Analyses of pro-fibrotic genes in renal
fibroblasts revealed a significant increase in α-Sma, Tgfb1, and
Col1a1 expression in fibroblasts exposed to mTECs pre-treated
with AA (Figure 7B). Following treatment with MSC-EVs,
this upregulation of pro-fibrotic genes was significantly reduced
(Figure 7B), therefore confirming the direct effect of MSC-EVs
on activated fibroblasts.
MSC-EVs Reverse the Expression of
miRNAs Dysregulated in AAN
miRNAs have been reported to play a crucial role in the regulation
of genes involved in kidney injury (Chung and Lan, 2015).
Furthermore, it has also been very well established that EVs can
influence the regulation of nucleic acids such as miRNAs by
transduction or horizontal transfer to recipient cells or tissue
(Ratajczak et al., 2006; Deregibus et al., 2007; Valadi et al.,
2007). The regulation of miRNAs by MSC-EVs, following AA
injury in mice, was evaluated using the mouse Fireplex miRNA
assay. Out of the 65 miRNAs analysed, 13 were found to be
significantly dysregulated in mice injured with AA and 36 were
found to be significantly regulated following treatment with
MSC-EVs (Figure 8A) (Supplementary Tables S1, S2). The
comparison of miRNAs between AA and AA+MSC-EV groups,
revealed ten to be commonly regulated. Among them, seven
were significantly downregulated following MSC-EV treatment
(Figures 8B,C), whereas three miRNAs were upregulated with
respect to AA treated mice and healthy controls (Figures 8B,D).
Three out of the seven miRNAs were validated through RT-PCR
(Supplementary Figure S1).
We further analysed the seven miRNAs (Figure 8C)
downregulated by MSC-EVs to identify the genes and pathways
regulated by them. The list of predicted target genes identified
through Mirwalk (data not shown), was further analysed
via Panther gene ontology software online. Ninety nine
pathways were predicted to be linked to miRNA targeted genes
(Supplementary Table S3) out of which the top 37 pathways
were selected based on a cut off of >5 genes/pathway and the
relevance of the pathway in kidney injury (Table 2). Furthermore,
analyses on validated pathways revealed the regulation of 14
pathways (Table 3). Interestingly, the majority of pathways
identified have been implicated in various pathological processes
such as fibrosis, inflammation, and apoptosis, all of which are
considered to be hallmarks of CKD. The list of all the miRNAs
that were identified to be regulated in the kidney tissues of
all the experimental mice groups analysed by Fireplex miRNA
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FIGURE 5 | Immunohistological staining of kidneys from mice treated with AA. Kidney paraffin-sections from healthy mice, or mice treated with AA, or AA mice
treated with MSC-EVs were stained for α-SMA (A), FSP-1 (B), or CD45 (C) to identify presence of active fibroblasts and inflammatory cell infiltration (original
magnification: 400X). (D) PDGFRβ/α-SMA staining was also performed to identify Pericyte/myofibroblast transition in the renal interstitium of kidney paraffin-sections
from AAN mice experimental groups (original magnification: 400X). The histograms represent the quantification of cells positive for the relative immunostaining in
mouse kidney paraffin-sections from AAN mice experimental groups. Data represent mean ± SEM of the fluorescence intensity of cells positive per high power field
measured from 10 images taken at random from six samples per treatment. ∗∗∗p < 0.001 AA vs. control or AA+MSC−EVs vs. AA. A one way ANOVA with
Bonferroni’s multi comparison test was performed. ∗ and $: AA vs. Control, p < 0.001; & and #: AA+MSC−EV vs. AA, p < 0.001.
assay can be found in the Supplementary Data (Supplementary
Tables S4, S5).
DISCUSSION
The current study demonstrates the capacity of MSC-EVs to
inhibit the progression of kidney injury in a CKD murine model
of AAN. Following MSC-EV treatment, mice showed an overall
improvement in kidney function, as reflected by a significant
reduction of blood creatinine, and BUN levels. In addition, MSC-
EVs significantly reduced tubular necrosis, interstitial fibrosis and
favoured renal regeneration. Furthermore, a marked reduction
in inflammatory cells, active fibroblasts, and pericytes was also
observed after MSC-EV treatment.
Over the last decade, the role of stem-cell derived EVs,
as an alternative strategy for tissue regeneration, has evolved
tremendously. In particular, MSC-EVs have been extensively
studied in various experimental disease models (Grange et al.,
2019a). For instance, in the classical CKD model of ureter urinary
obstruction (UUO), intravenous administration of MSC-EVs
not only improved renal function in a span of two weeks, but
also alleviated tubular injury and interstitial fibrosis (He et al.,
2015). Interestingly, in a porcine model of renovascular disease
(RVD), a more diverse model of CKD, a single dose of MSC-
EVs alleviated renal inflammation through the regulation of
pro and anti-inflammatory cytokines, contributing to recovery
(Eirin et al., 2017).
Alternative sources of MSC-EVs have also proven to be
effective. For example, urine derived MSC-EVs reduced podocyte
and tubular epithelial cell apoptosis and increased proliferation
of glomerular endothelial cells, therefore exhibiting an overall
regenerative effect in a rat model of diabetic nephropathy (Jiang
et al., 2016). Along the same line, Nagaishi et al. (2016) showed
that administration of MSC exosomes under the renal capsule,
in a similar mouse model of diabetic nephropathy, resulted in
equivalent anti-apoptotic effects and general improvement of
renal morphology.
More recently, our group reported the therapeutic effects of
multiple sources of stem-cell derived EVs, in a mouse model
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FIGURE 6 | MSC-EVs downregulate pro-fibrotic genes in mice treated with AA. Gene expression levels of α-Sma (A), Col1a1 (B), Tgfb1 (C), and Ltbp1 (D) in mice
treated with vehicle alone (control), or mice treated with AA, or AA mice treated with MSC-EVs. Data show mean ± SEM of n = 7 samples per treatment.
∗∗∗p < 0.001 AA vs. control, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 AA+MSC−EVs vs. AA. A one way ANOVA with Bonferroni’s multi comparison test was
performed.
of streptozotocin induced diabetic nephropathy (Grange et al.,
2019b). Grange et al. (2019b) showed that the administration
of EVs derived from both MSCs and HLSCs in diabetic
mice, significantly reduced, to near normal levels, the elevated
kidney functional parameters plasma creatinine, BUN and
albumin/creatinine excretion. In addition, the authors also
observed a significant reduction of fibrosis both at a protein
and molecular level, as a result of MSC-EV and HLSC-EV
treatment. A comparative miRNA expression analysis between
both EV types highlighted the presence of some common and
some uncommon miRNAs linked to the regulation of pro-
fibrotic genes. These findings further supported the anti-fibrotic
effect of MSC-EV, in a curative model of CKD (Grange et al.,
2019b). In addition, the regenerative effect of HLSC-EVs was
also reported by our lab, in an alternative model of CKD.
We demonstrated that in the CKD model of AAN, HLSC-
EVs not only improved the overall kidney function, but also
alleviated interstitial fibrosis and contributed to tubular repair.
The underlying repairing mechanisms were partially attributed to
the regulation of genes and miRNAs involved in the progression
of the disease (Kholia et al., 2018).
In the current study, using the same CKD model of AAN,
we attempted to evaluate the effect of MSC-EVs. We particularly
sought to identify similarities in the amelioration of kidney
damage and possible differences in the underlying molecular
mechanisms between MSC and HLSC EV sources.
The pathogenesis of CKD primarily involves dysfunction
of the local parenchyma in the form of tubular damage that
eventually progresses to necrosis and formation of hyaline casts
(Grange et al., 2019a). This phase of kidney injury is directly
correlated with an impairment of renal function, observed
through elevated blood BUN and creatinine levels as well as loss
of body weight as observed in various experimental models of
AAN (Zhou et al., 2010; Yuan et al., 2011; Bruno et al., 2012;
Huang et al., 2013; Grange et al., 2019b).
In the current study, the administration of AA increased
tubular damage and necrosis, as well as the levels of blood
creatinine and BUN. A gradual loss of mouse body weight,
over the course of the time, was also observed. Treatment
with MSC-EVs ameliorated tubular necrosis and reduced
blood BUN and creatinine levels. This effect was similar to
the one previously described following HLSC-EV treatment
(Kholia et al., 2018). However, at variance with HLSC-EVs, no
significant improvement in body weight was observed in mice
treated with MSC-EVs.
The activation of inflammatory, fibrotic, and reparative
processes occur simultaneously to promote regeneration and
repair, following an insult. An increase in the infiltration
of inflammatory and pro-fibrotic cells can impair tissue
regeneration and lead to fibrosis (Black et al., 2019). Renal fibrosis
characterised by progressive tissue scarring is a hallmark of CKD
and a prominent feature of AAN. Most of the patient cases of
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FIGURE 7 | MSC-EVs downregulate pro-fibrotic genes in kidney cortical fibroblasts in an in vitro model of AAN. (A) An illustration depicting the AAN in vitro assay
whereby: mTECs treated with or without AA for 4 hrs were co-cultured with mouse fibroblasts (mkCF) in the presence or absence of MSC-EVs (75,000 EVs/cell) for
5 days at 37◦C. (B) Gene expression analyses revealed an upregulation of the profibrotic markers: α-Sma, Tgfb1, and Col1a1 in mkCFs co-cultured with AA treated
mTECs. The expression levels of all three pro-fibrotic genes were reduced significantly following treatment with MSC-EVs. The data represents the mean ± SEM of
three independent experiments performed in quadruplicate. **p < 0.01 vs. AA, ***p < 0.001 vs. AA. A one way ANOVA with Bonferroni’s multi comparison test was
performed.
AAN, described in the literature, link chronic kidney failure with
fibrosis accompanied with interstitial inflammatory infiltrates
(Lo et al., 2004; Yang et al., 2007, 2012). In addition, various
experimental models of AAN also describe fibrosis, as a common
feature initiated mainly by the combination of inflammatory cells
and infiltration/activation of resident fibroblasts (Pozdzik et al.,
2008a; Sato and Yanagita, 2017).
Pozdzik et al. (2008a) reported the accumulation of cells
positive for vimentin and α-smooth muscle actin, both markers of
activated fibroblasts, in the renal interstitium of rats intoxicated
with AA. This was further confirmed by Huang et al. (2013)
in their mouse model of AAN, whereby an influx of FSP-
1 positive cells was observed in the kidneys of AA treated
mice. Furthermore, infiltration/activation of fibroblasts was
accompanied by the inflow of CD45 positive inflammatory cells,
as well as activated mononuclear and cytotoxic T cells (Pozdzik
et al., 2008a; Huang et al., 2013).
Along the same line, in our model of AAN, intoxication
with AA induced an influx of inflammatory cells (CD45 positive
cells) and myofibroblast activation (FSP-1 positive cells, and
α-SMA staining) in the renal interstitium, which was alleviated by
HLSC-EV treatment (Kholia et al., 2018). Interestingly, the same
effect was observed in our current study with MSC-EVs. Mice
that received treatment with MSC-EVs, showed a significantly
lower expression of CD45 positive cells, FSP-1 and α-SMA
positive myofibroblasts. As NSG mice lack an adaptive immune
system due to their genetic background (Shultz et al., 2005),
we speculate that, the CD45 positive cells are likely to be part
of the innate immune system. As a severe kidney injury was
observed in NSG mice following AA injection, we speculate that
the mechanism of injury could be mainly related to the innate
immune system. To explore the role of the adaptive immune
system, immunocompetent mice need to be used. However, in
the current study, as the MSC-EVs were derived from human
origin, immunodeficient mice had to be used to avoid an
immune reaction related to xenogenic material. Overall, our data
indicate that MSC-EVs attenuate the innate immune response
ameliorating AA induced kidney injury.
Another cell type known to play an important role in
fibrosis is the pericyte. They have been identified as a major
source of myofibroblasts in interstitial fibrosis (Wang et al.,
2017). These perivascular cells rich in PDGFRβ mainly provide
support to the vasculature under physiological conditions.
However, during a pathological insult in the kidney, they
tend to migrate toward the renal interstitium and undergo
transition into myofibroblasts positive for α-SMA (Wang et al.,
2017). In the current model, mice intoxicated with AA had a
significantly high number of pericyte/myofibroblast transitioned
cells (positive for PDGFRβ/α-SMA), which was significantly
reduced following MSC-EV treatment. The reduction in
interstitial fibrosis was also observed at a molecular level, whereby
a downregulation of the pro-fibrotic genes α-Sma, Col1a1, and
Tgfb1 was detected in kidneys of mice treated with MSC-EVs.
In vitro experiments on fibroblasts co-cultured with AA injured
mTECs further supported a role of MSC-EVs as mediators
of myofibroblast activation, as downregulation of pro-fibrotic
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FIGURE 8 | FirePlex miRNA assay. miRNAs, regulated in kidney toxicity, were detected in paraffin kidney sections in mice from all experimental groups (n = 3 per
group). (A) Venn diagram comparing the miRNAs regulated by AA and by MSC-EVs in the AAN model. Thirteen miRNAs were dysregulated in AA intoxicated mice
with respect to control mice and 36 in AA mice treated with MSC-EVs. Ten miRNAs were found to be common between the two groups. (B) List of the 10 modified
miRNAs common between AA mice and AA mice treated with MSC-EVs. (C) Box plots representing the miRNAs that were upregulated in mice injured with AA and
downregulated following treatment with MSC-EVs. (D) Box plots representing the miRNAs that were common between AA mice and AA mice treated with MSC-EVs
but not downregulated.
genes was observed following MSC-EV treatment. Furthermore,
a marked increase in proliferating cells, as evaluated by
PCNA staining and a significant reduction in apoptotic cells
evaluated by TUNEL staining, was observed in mice treated
with MSC-EVs, further supporting the activation of a renal pro-
regenerative programme. These findings demonstrate the anti-
inflammatory/anti-fibrotic properties of MSC-EVs, previously
described for HLSC-EVs in various models of CKD (Kholia et al.,
2018; Grange et al., 2019b).
TGFβ-1, a key factor in fibrosis was subsequently analysed
in our model. It is a major regulator of the pro-fibrotic process
leading to the development of scar tissue and ultimately end stage
renal disease (Jadot et al., 2017). The dysregulation of TGFβ-1 has
been reported in various experimental models of AAN (Pozdzik
et al., 2008b; Wang et al., 2008). In line with these studies, we also
observed a significant upregulation of TGFβ-1, at molecular level,
in mice damaged with AA. Interestingly, this upregulation was
further reverted following treatment with MSC-EVs. A similar
trend was also observed in the expression of the ltbp1 gene which
encodes for the LTBP1 protein, involved in the activation of
TGFβ-1. Of note, these data suggest a possible mechanism of
action of MSC-EVs in the regulation of TGFβ-1, which itself is a
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TABLE 2 | Panther gene ontology pathway analyses.
Pathways predicted by PANTHER online meta-analyses No of genes
involved
Wnt signalling pathway (P00057) 138
Inflammation mediated by chemokine and cytokine signalling
pathway (P00031)
94
Angiogenesis (P00005) 91
Cadherin signalling pathway (P00012) 77
Integrin signalling pathway (P00034) 73
PDGF signalling pathway (P00047) 71
EGF receptor signalling pathway (P00018) 69
FGF signalling pathway (P00021) 58
TGF-beta signalling pathway (P00052) 53
Apoptosis signalling pathway (P00006) 52
p53 pathway (P00059) 44
Interleukin signalling pathway (P00036) 42
Endothelin signalling pathway (P00019) 40
T cell activation (P00053) 39
Ras Pathway (P04393) 35
B cell activation (P00010) 33
Oxidative stress response (P00046) 31
VEGF signalling pathway (P00056) 29
Toll receptor signalling pathway (P00054) 26
PI3 kinase pathway (P00048) 24
Notch signalling pathway (P00045) 24
Interferon-gamma signalling pathway (P00035) 23
FAS signalling pathway (P00020) 15
Hypoxia response via HIF activation (P00030) 14
GABA-B receptor II signalling (P05731) 13
p53 pathway by glucose deprivation (P04397) 13
Histamine H1 receptor mediated signalling pathway (P04385) 13
Heterotrimeric G-protein signalling pathway-rod outer segment
phototransduction (P00028)
11
Hedgehog signalling pathway (P00025) 11
General transcription regulation (P00023) 11
JAK/STAT signalling pathway (P00038) 10
Beta3 adrenergic receptor signalling pathway (P04379) 10
Glycolysis (P00024) 10
DNA replication (P00017) 9
Angiotensin II-stimulated signalling through G proteins and
beta-arrestin (P05911)
8
Cell cycle (P00013) 7
P53 pathway feedback loops 1 (P04392) 6
Predicted pathways regulated by miRNAs downregulated by MSC-EVs in AA mice.
The top 37 pathways have been selected on the basis of number of genes involved
in kidney injury.
key stone in the progression of inflammation and fibrosis (Wang
et al., 2008; Black et al., 2019).
miRNAs are non-coding RNA molecules, that function as
post-transcriptional regulators, blocking target mRNAs. Their
role in regeneration has been gaining an increasing interest
over the past decade (Ignarski et al., 2019). Various studies
have reported the altered expression of miRNAs in renal tissue
during the progression of acute and CKDs, both in human and
animal models (Trionfini et al., 2015). In addition, miRNAs
TABLE 3 | Panther pathway enrichment analyses on validated target genes of
differentially expressed miRNAs in AA mice treated with MSC-EVs.
Pathways validated by PANTHER online meta-analyses No of genes
involved
Angiogenesis (P00005) 12
Apoptosis signalling pathway (P00006) 10
Integrin signalling pathway (P00034) 10
PDGF signalling pathway (P00047) 9
CCKR signalling map (P06959) 9
TGF-beta signalling pathway (P00052) 8
Gonadotropin-releasing hormone receptor pathway (P06664) 8
p53 pathway (P00059) 7
p53 pathway feedback loops 2 (P04398) 7
Inflammation mediated by chemokine and cytokine signalling
pathway (P00031)
6
FGF signalling pathway (P00021) 6
FAS signalling pathway (P00020) 6
EGF receptor signalling pathway (P00018) 6
Oxidative stress response (P00046) 6
enriched in EVs, have been shown to exert their biological
action by being directly transferred into recipient cells or
indirectly by influencing the cells genetic content (Ratajczak
et al., 2006; Deregibus et al., 2007). We therefore, sought to
investigate, the dysregulation of miRNAs in our current model
of AAN. Seven miRNAs were identified to be upregulated in
AA intoxicated kidneys, and downregulated following MSC-EV
treatment. Interestingly, these miRNAs have been reported to
play a role in kidney fibrosis. For instance, Thum et al. (2008) first
reported the overexpression of miR21 in a fibrosis model of heart
failure, while subsequent studies demonstrated its involvement
in various other models, including kidney fibrosis (Liu et al.,
2010; Denby et al., 2011). In another study, the upregulation of
miR34a was found to be elevated in the interstitium of mouse
fibrotic kidneys subjected to UUO injury (Zhou et al., 2014). In
addition, both miR132-3p and miR214 have been found to be
upregulated in various models of kidney diseases and associated
with inflammation, apoptosis, myofibroblast activation, and
dysregulation of the extracellular matrix (Denby et al., 2011, 2014;
Bijkerk et al., 2016). Furthermore, attenuation of these miRNAs
through inhibition or silencing has been shown to ameliorate the
various forms of kidney diseases by downregulating pathways
and processes favoring the progression of injury and fibrosis
(Denby et al., 2011; Liu et al., 2019).
Bioinformatic meta-analysis was performed on the predicted
and validated target genes of these 7 miRNAs for the relative
pathways to be identified. Through online Panther pathway
analysis, we identified over 30 predicted pathways out of which
some were linked with kidney injury and paralleled with the
ones regulated by HLSC-EVs in our previous study (Kholia
et al., 2018). Among some of these pathways, the WNT/beta-
catenin signalling pathway, chemokine/cytokine pathway, and
the TGFβ signalling pathway were identified. On the other hand,
the validated pathways regulated by the 7 miRNAs mentioned
above, were much less (14 pathways) in comparison with the
validated pathways regulated by HLSC-EVs (data not shown).
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Nonetheless, this study allowed us to identify validated pathways
that were specifically regulated by MSC-EVs which include:
apoptosis, TGFβ, FAS, and P53 signalling pathways amongst
others that have been reported to play a role in CKD (Chung and
Lan, 2015; Kholia et al., 2018; Black et al., 2019; Grange et al.,
2019b). Moreover, the comparison between miRNAs regulated by
MSC-EVs in the current study and HLSC-EVs in our previous
study (Kholia et al., 2018), showed no overlap, suggesting that
the molecular targets of stem cell derived EVs could differ despite
their overall common therapeutic effect.
Various studies have been performed in our lab to identify
the active biological molecules responsible for the therapeutic
effects observed. For instance, proteomics studies, performed
by Collino et al. (2017) on MSC-EV fractions, revealed the
presence of cytokines, chemokine receptors such as CXCR1,
CXCR6 etc; interleukins such as IL13, IL10, IL 4, that are
involved in regulating multiple immunomodulatory, and anti-
inflammatory pathways. In an earlier study by Collino et al.
(2015), EVs from wild-type MSCs induced morphological and
functional recovery of the kidneys in a mouse model of AKI,
whereas EVs from drosha-knockdown MSCs that had a global
downregulation of microRNAs were ineffective. They showed,
through RNA sequencing and gene ontology analysis that kidney
genes dysregulated post AKI (that mainly influenced pathways
related to inflammation, matrix-receptor interaction, among
others) were reverted after treatment with wild-type MSC-
EVs but not EVs from drosha-knockdown MSCs. Therefore,
confirming the contribution of miRNAs towards MSC-EV
biological activity. In a recent study by Grange et al. (2019b),
molecular analysis of MSC-EVs revealed enrichment with
miRNAs that regulated various inflammatory and pro-fibrotic
pathways therefore further confirming part of the EV therapeutic
effects to the miRNA content. Although, multiple reports have
been published dissecting the contents of stem cell derived EVs
to identify the active content responsible for their biological
activity, the demonstration that single or multiple component are
responsible for their specific function are still very challenging.
CONCLUSION
Our data suggest that multiple injections of MSC-EVs not only
improved renal function, but also ameliorated kidney fibrosis,
and tubular necrosis, possibly by attenuating the infiltration of
inflammatory cells and myofibroblasts, as well as by reducing the
transition of pericytes to myofibroblasts. Although the various
regenerative effects of MSC-EVs on AA injured mice were
similar to those previously observed with HLSC-EVs on the same
model of AAN (Kholia et al., 2018), the biological effect exerted
by both EV sources, can be ascribed to different underlying
molecular mechanisms.
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